News
-
-
-
COMMUNIQUÉ DE PRESSE
Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024
Kuros Biosciences reports 149% increase in direct MagnetOs sales and surpasses cash flow breakeven in the first nine months of 2024. Company's financial highlights and future outlook highlighted -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft
Kuros Biosciences announces the publication of MagnetOs MAXA Level 1 study outcomes in Spine, showing superiority over autograft. Study details effectiveness of MagnetOs in posterolateral fusions -